Nanoparticle-Based Delivery Systems for Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccine Adjuvants".
Deadline for manuscript submissions: 28 February 2026 | Viewed by 1438
Special Issue Editor
Interests: adjuvant; multiepitope vaccine; humoral response; cellular response; recombinant vaccine; vaccinology; vaccine delivery vehicle
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Developing advanced vaccines is crucial for effectively combating human and animal diseases and improving global well-being. Nanotechnology has significantly enhanced vaccine design, resulting in innovative approaches such as virus-like particle (VLP)-based vaccines, RNA vaccines, and new adjuvants that boost vaccine efficacy.
This Special Issue aims to include advancements in vaccine efficacy achieved through nanomaterials to deliver protective antigens. It will also examine vaccine antigens with advantages such as easy purification and high immunogenicity. Additionally, the issue will explore nanomaterials used for alternative routes of administration, particularly those for mucosal vaccines, which hold promise for achieving protective immunity against various diseases. Furthermore, nanoparticles with immunostimulatory properties that can serve as vaccine adjuvants are also interesting.
We encourage original research articles and reviews covering research areas that may include antigen delivery using nanomaterials, nano-adjuvants, innovative vaccine antigens, and multifunctional nanoparticles.
We look forward to receiving your contributions.
Dr. Sergio Rosales-Mendoza
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- virus-like particle
- nanocage
- chimeric antigen
- mucosal vaccine
- nanoadjuvant
- nanoparticle
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
